#kenvue

[ follow ]
fromAdExchanger
15 hours ago

Ready, Set, 'Bo; Kimberly-Clark And Johnson & Johnson | AdExchanger

Fubo's quarterly revenue for North America declined 2.3% year over year to $386 million, and advertising revenue declined 7% to $25 million, which CFO John Janedis attributed to "the absence of certain ad-insertable content." (Meaning, in other words, their previous content deals with TelevisaUnivision and WBD.) But despite those declines, Fubo's leadership thinks the advertising outlook is pretty good. Upfront commitments for the 2025-2026 are up 26% compared to last season, with nearly a third of those advertisers being new to Fubo.
Business
#mergers--acquisitions
fromFast Company
1 day ago
Business

KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama

fromFast Company
1 day ago
Business

KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama

#tylenol-acetaminophen
fromFast Company
1 month ago
US politics

KVUE stock price: Kenvue plummets as Trump announcement expected to tie Tylenol to autism, tout leucovorin

fromFortune
1 month ago
US news

Tylenol maker's stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a 'major overreaction' | Fortune

fromFast Company
1 month ago
US politics

KVUE stock price: Kenvue plummets as Trump announcement expected to tie Tylenol to autism, tout leucovorin

fromFortune
1 month ago
US news

Tylenol maker's stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a 'major overreaction' | Fortune

fromAxios
1 month ago

Tylenol maker Kenvue blasts Trump administration's autism claim

"acetaminophen is the safest pain reliever option for pregnant women as needed throughout their entire pregnancy"
US politics
#acetaminophen
fromFortune
1 month ago
Public health

Tylenol-maker Kenvue's stock has lost a quarter of its value in 6 months as momentum grows for autism link despite repeated denials | Fortune

fromFortune
1 month ago
Public health

Tylenol-maker Kenvue's stock has lost a quarter of its value in 6 months as momentum grows for autism link despite repeated denials | Fortune

E-Commerce
fromFortune
3 months ago

Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors

Kenvue faces challenges in growth and profitability, leading to CEO resignation and strategic review after a 4% expected drop in net sales.
[ Load more ]